Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine Oakman

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
Triple negative breast cancer: a heterogeneous subgroup defined by what it is notCatherine Oakman, Erica Moretti, Giulia Pacini, et al.
Journal of the National Cancer Institute|November 7, 2009
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapyCatherine Oakman, Erica Moretti, Christos Sotiriou, et al.
Breast Cancer Research : BCR|May 14, 2009
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancerCatherine Oakman, Silvia Bessi, Elena Zafarana, et al.
The International Journal of Biochemistry & Cell Biology|May 13, 2010
Uncovering the metabolomic fingerprint of breast cancerCatherine Oakman, Leonardo Tenori, Laura Biganzoli, et al.
Breast (Edinburgh, Scotland)|October 22, 2011
Adjuvant systemic treatment for individual patients with triple negative breast cancerCatherine Oakman, Erica Moretti, Francesca Galardi, et al.
Breast (Edinburgh, Scotland)|November 17, 2009
Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more?Catherine Oakman, Marta Pestrin, Egidia Cantisani, et al.
Molecular Oncology|August 25, 2014
Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective studyLeonardo Tenori, Catherine Oakman, Patrick G Morris, et al.
Molecular Oncology|June 13, 2012
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot studyLeonardo Tenori, Catherine Oakman, Wederson M Claudino, et al.
Pilot and Feasibility Studies|June 13, 2017
Assessing the usefulness and acceptability of a low health literacy online decision aid about reproductive choices for younger women with breast cancer: the aLLIAnCE pilot study protocolMichelle Peate, Sian Karen Smith, Victoria Pye, et al.
Future Oncology (London, England)|October 11, 2013
TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancerErica Moretti, Christine Desmedt, Chiara Biagioni, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
European Journal of Cancer (Oxford, England : 1990)|September 28, 2011
Triple negative breast cancer: a heterogeneous subgroup defined by what it is notCatherine Oakman, Erica Moretti, Giulia Pacini, et al.
Journal of the National Cancer Institute|November 7, 2009
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapyCatherine Oakman, Erica Moretti, Christos Sotiriou, et al.
Breast Cancer Research : BCR|May 14, 2009
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancerCatherine Oakman, Silvia Bessi, Elena Zafarana, et al.
The International Journal of Biochemistry & Cell Biology|May 13, 2010
Uncovering the metabolomic fingerprint of breast cancerCatherine Oakman, Leonardo Tenori, Laura Biganzoli, et al.
Breast (Edinburgh, Scotland)|October 22, 2011
Adjuvant systemic treatment for individual patients with triple negative breast cancerCatherine Oakman, Erica Moretti, Francesca Galardi, et al.
Breast (Edinburgh, Scotland)|November 17, 2009
Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more?Catherine Oakman, Marta Pestrin, Egidia Cantisani, et al.
Molecular Oncology|August 25, 2014
Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective studyLeonardo Tenori, Catherine Oakman, Patrick G Morris, et al.
Molecular Oncology|June 13, 2012
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot studyLeonardo Tenori, Catherine Oakman, Wederson M Claudino, et al.
Pilot and Feasibility Studies|June 13, 2017
Assessing the usefulness and acceptability of a low health literacy online decision aid about reproductive choices for younger women with breast cancer: the aLLIAnCE pilot study protocolMichelle Peate, Sian Karen Smith, Victoria Pye, et al.
Future Oncology (London, England)|October 11, 2013
TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancerErica Moretti, Christine Desmedt, Chiara Biagioni, et al.
Pageof 3